Skip to content

Neobiomics AB and ExCEEd Orphan s.r.o. announce an extended partnership for
ProPrems® in Estonia, Latvia and Lithuania

Stockholm, Sweden, 17 Nov 2022 – Neobiomics AB and ExCEEd Orphan s.r.o. have agreed to extend their partnership towards new territories within the Baltics. After collaborating over an exclusive distribution agreement for 14  countries in Central and Eastern Europe (CEE), the extended agreement will now also include Estonia, Latvia, and  Lithuania. The agreement includes marketing and sales of Neobiomics’ proprietary product ProPrems® and is in  effect immediately. 

Neobiomics is a Sweden-based company specializing in the area of neonatal and child health care and ExCEEd  Orphan s.r.o. is a Czech Republic-based company focused on products for the treatment of rare diseases. 

Dr. Stefan Johansson, CEO, and Founder of Neobiomics regards the agreement as another important step for  ProPrems® market expansion: “We at Neobiomics are very happy to have found such a good partner in ExCEEd  Orphan. Their successful introduction of ProPrems® into the CEE region makes us confident about a quick uptake of  ProPrems® also in the Baltics.” 

Jiri Hermanek, CEO and Founding Partner of ExCEEd Orphan comments: “ProPrems®, Neobiomics’ high-quality multi strain food supplement for premature newborns, has proven valuable for our portfolio in the CEE countries. We are  now looking forward to bringing ProPrems® to the Baltic countries together with Neobiomics.” 

About Neobiomics 

Neobiomics AB, founded in 2016 by Stefan Johansson and Philipp Novak, is an alumni member of the  Innovation Incubator at Karolinska Institutet Innovation AB. The first product ProPrems® is a high-quality multi strain food supplement manufactured by Chr. Hansen is a worldwide leader in manufacturing bacterial cultures.  ProPrems® is now available in a majority of European countries and continues its geographical expansion within  Europe.  

About ExCEEd Orphan s.r.o. 

ExCEEd Orphan s.r.o. was founded in 2018 by 5 rare disease experts from multiple CEE countries. The company is  focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines  in this field. The portfolio of ExCEEd Orphan includes products in therapeutic areas like hematology, neurology,  immunology, and metabolic diseases. 

For further information, please refer to and